SNSW(688117) Zheng Quan Zhi Xing·2025-03-30 09:13Group 1 - The company expects a net profit attributable to shareholders of the parent company for Q1 2025 to be between 39.1985 million yuan and 55.000 million yuan, representing an increase of 137.97% to 190.85% compared to the same period last year [1][2] - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between 39.8396 million yuan and 48.6929 million yuan, which is an increase of 160.62% to 218.54% year-on-year [1][2] - The company reported a net profit of 16.4722 million yuan for the same period last year, with a net profit of 15.2864 million yuan after deducting non-recurring gains and losses [1][2] Group 2 - The significant increase in performance is attributed to the company's alignment with the development trends in the peptide industry and the expansion of its domestic and international marketing efforts, leading to substantial growth in sales revenue from peptide raw materials in Q1 2025 [2]